Skip to content

bluebird bio, Inc.: financial reference

Explore bluebird bio, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2024-12-31460,232,000USD2025-03-27
Total liabilitiesAt date2024-12-31491,766,000USD2025-03-27
Stockholders equityAt date2024-12-31-31,534,000USD2025-03-27
Cash and cash equivalentsAt date2024-12-3162,305,000USD2025-03-27
Net income or loss2024-01-012024-12-31-240,715,000USD2025-03-27
Operating cash flow2024-01-012024-12-31-260,020,000USD2025-03-27
Capital expenditure payments2024-01-012024-12-312,599,000USD2025-03-27
Revenue2024-01-012024-12-3183,807,000USD2025-03-27
Contract revenue excluding tax2024-01-012024-12-3183,795,000USD2025-03-27
Financing cash flow2024-01-012024-12-3187,469,000USD2025-03-27
Investing cash flow2024-01-012024-12-313,897,000USD2025-03-27
Retained earnings or deficitAt date2024-12-31-4,501,043,000USD2025-03-27
Basic weighted-average shares2024-01-012024-12-319,689,000shares2025-03-27
Diluted weighted-average shares2024-01-012024-12-319,689,000shares2025-03-27
Basic earnings per share2024-01-012024-12-31-24.84USD/shares2025-03-27
Diluted earnings per share2024-01-012024-12-31-24.84USD/shares2025-03-27
Income tax expense or benefit2024-01-012024-12-3170,000USD2025-03-27
Net property, plant and equipmentAt date2022-12-319,362,000USD2023-03-29
Share-based compensation expense2024-01-012024-12-3113,737,000USD2025-03-27
Operating income or loss2024-01-012024-12-31-270,461,000USD2025-03-27
Current assetsAt date2024-12-31154,668,000USD2025-03-27
Current liabilitiesAt date2024-12-31321,462,000USD2025-03-27
Current accounts payableAt date2024-12-3134,316,000USD2025-03-27
Goodwill carrying amountAt date2024-12-315,646,000USD2025-03-27
Net finite-lived intangible assetsAt date2024-12-319,547,000USD2025-03-27
Operating expenses2018-01-012018-12-31626,602,000USD2019-02-21
Net inventoryAt date2024-12-3165,017,000USD2025-03-27
Gross profit2024-01-012024-12-31-5,573,000USD2025-03-27
Cost of revenue2024-01-012024-12-3189,380,000USD2025-03-27
Selling, general and administrative expense2024-01-012024-12-31167,874,000USD2025-03-27
Research and development expense2024-01-012024-12-3194,252,000USD2025-03-27
Common shares outstandingAt date2024-12-319,728,000shares2025-03-27
Cash including restricted cashAt date2024-12-31105,943,000USD2025-03-27
Additional paid-in capitalAt date2024-12-314,469,719,000USD2025-03-27
Accumulated other comprehensive income or lossAt date2024-12-31-2,133,000USD2025-03-27
Operating lease right-of-use assetAt date2024-12-31176,883,000USD2025-03-27
Operating lease liabilityAt date2024-12-31186,688,000USD2025-03-27
Gross property, plant and equipmentAt date2022-12-3131,294,000USD2023-03-29
Accumulated depreciation on property, plant and equipmentAt date2022-12-3121,932,000USD2023-03-29
Net intangible assets excluding goodwillAt date2024-12-319,547,000USD2025-03-27
Other noncurrent assetsAt date2024-12-3152,640,000USD2025-03-27
Other noncurrent liabilitiesAt date2024-12-31947,000USD2025-03-27
Prepaid expenses and other current assetsAt date2016-12-3119,836,000USD2017-02-22
Current contract liabilitiesAt date2022-12-311,502,000USD2023-03-29
Pre-tax income or loss from continuing operations2022-01-012022-12-31-266,461,000USD2023-03-29
Profit or loss including noncontrolling interests2019-01-012019-12-31-789,608,000USD2020-02-18
Comprehensive income or loss2024-01-012024-12-31-241,052,000USD2025-03-27
Net income available to common stockholders2014-01-012014-12-31-48,709,000USD2015-02-25
General and administrative expense2018-01-012018-12-31174,129,000USD2019-02-21
Depreciation, depletion and amortization2024-01-012024-12-3160,300,000USD2025-03-27
Amortization of intangible assets2024-01-012024-12-31900,000USD2025-03-27
Other nonoperating income or expense2024-01-012024-12-3144,177,000USD2025-03-27
Nonoperating income or expense2015-01-012015-12-312,314,000USD2016-02-25
Interest paid, net2021-01-012021-12-310USD2022-03-04
Income taxes paid, net2024-01-012024-12-31-10,000USD2025-03-27
Proceeds from issuing common stock2024-01-012024-12-310USD2025-03-27
Operating lease payments2024-01-012024-12-3121,202,000USD2025-03-27
Change in inventories2024-01-012024-12-3152,460,000USD2025-03-27
Change in accounts payable2024-01-012024-12-3116,504,000USD2025-03-27

Filings

48 bluebird bio, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
bluebird bio, Inc. / CIK 0001293971
Captured
2026-09-21T17:19:03.388Z
SEC response SHA-256
858d78d54f5bae3df00559b64af5a3aba62be12d2317b727228e8ddef2ef50ea

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001293971.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))